MUCOMMUNE LLC

Search SAM.gov-registered contractors by mission sector, compliance posture and contract vehicle.

Mission sectors

Live demo

Arclight Demo Aerospace & Defense, Inc.

UEI DEMOPRIMEC01 · CAGE 0DEMO · Prime Corporate

CMMC Level 2 (C3PAO)
6 contract vehicles
Case studies & key people
Photo gallery & brand

See the finished profile Download it as an AI-ready Markdown file

A fictional company, built to show every section filled in.

Looking for something specific? Tour the demo profile

Open solicitations, teaming requests and recompetes, from SAM.gov and USAspending.

Pipeline

Popular vehicles

Try an example search

Real filters on live federal data. One click opens the results.

Looking for something specific? Tour the demo profile

AI capture analysis, capability statement grading and plain-language guides.

Analyze

Learn

Ask the AI Capture Analyst

Teaming analysis, best-fit partners, RFP fit and compliance matrices, grounded in TeamingIndex data.

Open the Intelligence Hub Grade a capability statementFree score in seconds. The PDF is never stored.

Looking for something specific? Tour the demo profile

Teaming agreements and proposals, plus how TeamingIndex verifies, protects and connects your data.

Product

Trust

Claim your company, free

Verify your UEI with your work email and control how primes see you. Every badge shows who vouches for it and when.

Claim your profile

Your workspace

Profile, compliance, team, saved searches and billing.

Go to your dashboard

Compare plans

Looking for something specific? Tour the demo profile

See TeamingIndex with real data before you sign up: a finished profile and working searches.

Sample pages

Example searches

Live demo

Arclight Demo Aerospace & Defense, Inc.

UEI DEMOPRIMEC01 · CAGE 0DEMO · Prime Corporate

CMMC Level 2 (C3PAO)
6 contract vehicles
Case studies & key people
Photo gallery & brand

See the finished profile Download it as an AI-ready Markdown file

A fictional company, built to show every section filled in.

Looking for something specific? Tour the demo profile

Popular

See it with data

MUCOMMUNE LLC — UEI NWVPL2L4JMN8 | TeamingIndex

Proven teaming graph

Learn more

Who MUCOMMUNE LLC has actually worked with, from sub-awards that prime contractors report to the government. Use it to see which primes already trust this company.

No sub-award reports yet

Prime contractors report first-tier subcontracts of $30,000 or more. None name this company yet, which is common for companies that mostly win prime contracts or work below the reporting threshold.

See where agencies spend

Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.

SBIR/STTR portfolio

Learn more About SBIR/STTR

Small Business Innovation Research and Technology Transfer awards: early-stage federal R&D money this company has won.

SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects

Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.

Awards on record: 31 awards
Total awarded: $21,596,666
By phase: SBIR Phase I: 20
SBIR Phase II: 10

FedRAMP offerings

Learn more

Cloud services this company lists on the FedRAMP Marketplace, the government's record of cloud authorizations.

No FedRAMP Marketplace listing

No FedRAMP Marketplace listing is linked to this company. Cloud providers appear here automatically once FedRAMP lists their offering.

Find FedRAMP-authorized companies

Source: FedRAMP Marketplace · sync date not recorded

Exclusions & screening

Exclusions Screening list

Checks a prime runs before teaming: SAM.gov exclusions (debarment and suspension) and the government's Consolidated Screening List for export and sanctions lists.

SAM.gov exclusions

Not yet checked against SAM.gov exclusions.

Search exclusions on SAM.gov (opens in a new tab)

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

GSA CALC+ rate benchmark

Learn more

Hourly ceiling rates this company was awarded on GSA contracts, compared with the market for similar labor categories. Ceiling rates are the most an agency can be charged, not prices paid.

No GSA CALC+ rates on record

Companies with a GSA Multiple Award Schedule contract appear here after CALC+ publishes their awarded labor rates.

See GSA MAS holders

Source: GSA CALC+ awarded ceiling rates · sync date not recorded

Awards (most recent first)

SBIR: In vivo engineering of multifaceted B7H3.CAR-T cells for cellular immunotherapy of pancreatic ductal adenocarcinoma
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $1,146,618
Sep 16, 2025 – Aug 31, 2027
- Active
- Ends Aug 2027
Solicitation PA24-245 (2024) · Topic NCI
Development and evaluation of a pegloticase biobetter for sustained suppressionof fructose-induced obesity
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $359,608
Sep 15, 2025 – Aug 31, 2026
Solicitation PA24-245 (2024) · Topic 300
Fast Dissolving MM008 Tablet for Instant On-Demand Non-Hormonal Contraception
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $1,130,880
Sep 15, 2025 – Aug 31, 2027
- Active
- Ends Aug 2027
Solicitation PA24-245 (2024) · Topic NICHD
Development of MM010, a PEG-specific intervention that blocks allergic response and restores effective repeat dosing of peg-asparaginase in patients with acute lymphoblastic leukemia
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $409,732
Sep 12, 2025 – Aug 31, 2026
Solicitation PA24-245 (2024) · Topic 102
SBIR: In vivo engineering of B7-H3.CAR-T cells for ovarian cancer therapy
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $1,031,566
Sep 11, 2025 – Aug 31, 2027
- Active
- Ends Aug 2027
Solicitation PA24-245 (2024) · Topic NCI
Engineering a physiologically-tuned reservoir intravaginal ring releasing lactic acid for the treatment and prevention of bacterial vaginosis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $310,136
Aug 21, 2025 – Jul 31, 2027
- Active
Solicitation PA23-230 (2023) · Topic NIAID
IND-enabling development of MM-009, a reservoir-intravaginal ring for ultra-highrates of month-long lactic acid release to treat and prevent bacterial vaginosis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $1,025,000
Jun 23, 2025 – May 31, 2028
- Active
Solicitation PA24-245 (2024) · Topic NIAID
SUSTAINED RELEASE OF VRC07 FROM CAPSULE-INTRAVAGINAL RING FOR PREVENTING HIV TRANSMISSION
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $306,183
Solicitation PHS 2025-1 (2025) · Topic 138
IND-enabling development of MM010, a PEG-specific intervention that blocks allergic response and restores repeated dosing for select PEGylated medicines impacted by anti-PEG antibody
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2024 · $582,916
Jan 22, 2024 – Dec 31, 2026
- Active
Solicitation PA22-176 (2022) · Topic NIAID
Highly Acidifying Intravaginal Rings with Lactobacillus Probiotics to Treat Bacterial Vaginosis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $306,483
Apr 1, 2023 – Mar 31, 2024
Solicitation PA22-176 (2022) · Topic NIAID
SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $2,073,533
Mar 23, 2023 – Feb 28, 2025
Solicitation PA19-272 (2019) · Topic NIAID
IND‐enabling development of MM‐008 IVR, an antibody-based nonhormonal contraceptive intravaginal ring
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $2,067,567
Sep 19, 2022 – Aug 31, 2024
- Direct to Phase II
Solicitation PA20-262 (2020) · Topic NICHD
Fast dissolving antibody tablets for preventing vaginal HSV transmission
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $306,500
Sep 1, 2022 – Aug 31, 2023
Solicitation PA21-259 (2021) · Topic NIAID
User-based identification of preferred design features for MM008, a non-hormonal contraceptive vaginal ring
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $259,499
Sep 1, 2022 – Aug 31, 2023
Solicitation HD22-019 (2021) · Topic NICHD
Development of a qualified pharmacokinetic bioassay to support preclinical and clinical studies of MM-008, a non-hormonal contraceptive antibody
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $277,713
Jul 1, 2022 – Jun 30, 2023
Solicitation HD22-018 (2021) · Topic NICHD
Multipurpose vaginal ring for non-hormonal contraception and preventing bacterial vaginosis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $265,970
Aug 1, 2021 – Jul 31, 2022
Solicitation HD21-007 (2020) · Topic NICHD
Development of RespiraClear for targeted mucosal treatment of RSV infections
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2021 · $1,549,957
May 7, 2021 – Apr 30, 2023
Solicitation PA18-574 (2018) · Topic NIAID
Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2021 · $1,702,035
Apr 1, 2021 – Mar 31, 2023
Solicitation HD18-102 (2018) · Topic NICHD
SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $306,500
Mar 4, 2021 – Sep 3, 2022
Solicitation PA19-272 (2019) · Topic NIAID
Vaginal ring for sustained release of lactic acid to prevent bacterial vaginosis and associated health risks
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $306,500
Mar 1, 2021 – Feb 28, 2022
Solicitation PA19-272 (2019) · Topic NIAID
In vivo dose finding for an antibody based nonhormonal contraceptive intravaginal ring
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $1,729,789
Sep 15, 2020 – Aug 31, 2022
- Direct to Phase II
Solicitation PA19-272 (2019) · Topic NICHD
Aerosol immunotherapy for treatment of human metapneumovirus infection
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $261,742
Jul 1, 2020 – Jun 30, 2021
Solicitation PA19-272 (2019) · Topic NIAID
Inhaled 'muco-trapping' antibody as universal immunotherapy for influenza virus infections
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $275,437
Jun 23, 2020 – May 31, 2021
Solicitation PA19-272 (2019) · Topic NIAID
In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $1,994,684
Dec 20, 2019 – Nov 30, 2022
Solicitation PA18-574 (2018) · Topic NIAID
Development of RespiraClear for targeted mucosal treatment of RSV infections
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $224,961
Aug 19, 2019 – Jan 31, 2021
Solicitation PA18-574 (2018) · Topic NIAID

Showing the 25 most recent of 31 awards.

Compliance posture: unverified (SAM.gov baseline only)

About MUCOMMUNE LLC

Identifiers

Ready to team with MUCOMMUNE LLC?

Capabilities & differentiators

Compliance posture

Facility clearance

Past performance

Contract vehicles

Proven teaming graph

SBIR/STTR portfolio

FedRAMP offerings

Exclusions & screening

SAM.gov exclusions

GSA CALC+ rate benchmark

NAICS, PSC & socio-economic status

Teaming preferences

Business development contact

Corporate hierarchy

Data sources & provenance

Consolidated Screening List